CSIMarket
 

Dynavax Technologies Corporation  (DVAX)
Other Ticker:  
 

Dynavax Technologies's Working Capital Per Sales

DVAX's Working Capital and Revenue growth



DVAX Working Capital Per Revenue (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Working Capital Change 13.43 % 23.33 % 55.73 % 84.3 % 112.79 %
Y / Y Revenue Change -59.15 % -76.42 % -58.83 % -5.42 % 56.37 %
Working Capital Per Revenue 2.11 1.6 1.07 0.88 0.75
Total Ranking # 2604 # 2159 # 2380 # 998 # 1538
Seq. Working Capital Change 3.83 % 1.89 % -3.69 % 11.33 % 12.89 %
Seq. Revenue Change 13.72 % 28.39 % -74.57 % 9.99 % -34.34 %





Comment on DVAX's Working Capital Per Revenue in the third quarter 2023
Dynavax Technologies's Working Capital Per Revenue sequentially grew to 2.11 during the Q3 2023, below the Dynavax Technologies average. Due to increase of revenue in the Q3 2023 year on year by -59.15%.

Within Healthcare sector 76 other companies have achieved lower Working Capital Per Revenue during the Q3 2023. While Working Capital Per Revenue total ranking has deteriorated in the third quarter 2023, compared to previous quarter from 2159 to 2604.
Working Capital Per Revenue Ranking
Within: No.
Industry # 28
Sector # 77
S&P 500 # 2604


Working Capital Per Revenue Statistics
High Average Low
520.79
37.39
0.68
(Mar 31 2018)   (Jun 30 2022)



Financial Statements
Dynavax Technologies's Working Capital $ 781 Millions Visit DVAX's Balance sheet
Dynavax Technologies's Revenues $ 69 Millions Visit DVAX's Income Statement
Where are DVAX's Sales coming from? Visit DVAX's Sales by Geography




Companies with similar Average Working Capital Per Revenue for 12 months ending Sep 30 2023, within Healthcare Sector Working Capital Per Revenue
Alector Inc   5.69 
Arbutus Biopharma Corp  5.62 
Zevra Therapeutics Inc   5.59 
Inspiremd Inc   5.59 
Rapid Micro Biosystems Inc   5.51 
Zomedica Corp   5.42 
Merus N v   5.30 
Cara Therapeutics inc   5.28 
Hookipa Pharma inc   5.21 
Orchard Therapeutics Plc  5.14 
Mersana Therapeutics Inc   5.08 
Alpine Immune Sciences Inc   5.07 
Werewolf Therapeutics Inc   4.94 
Arvinas Inc   4.90 
Xenetic Biosciences Inc   4.88 
Uniqure N v   4.67 
Nektar Therapeutics  4.66 
Aligos Therapeutics Inc   4.59 
Prothena Corporation Public Limited Company  4.55 
Liquidia Corporation  4.48 
Eiger Biopharmaceuticals Inc   4.38 
Universal Biosensors Inc   4.37 
Repare Therapeutics Inc   4.34 
Perspective Therapeutics Inc   3.99 
Rhythm Pharmaceuticals inc   3.98 
Theravance Biopharma inc   3.96 
Pacific Biosciences Of California Inc   3.95 
Siga Technologies Inc  3.94 
Enanta Pharmaceuticals Inc  3.91 
Poseida Therapeutics Inc   3.87 
Date modified: 2023-11-03T16:14:08+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com